Afficher la notice abrégée

hal.structure.identifierDepartment of Experimental Therapeutics
dc.contributor.authorBARTHOLOMEUSZ, Geoffrey
hal.structure.identifierDepartment of Experimental Therapeutics
hal.structure.identifierDepartment of Chemistry
dc.contributor.authorCHERUKURI, Paul
hal.structure.identifierDepartment of Experimental Therapeutics
dc.contributor.authorKINGSTON, John
hal.structure.identifierDepartment of Chemistry
hal.structure.identifierCentre de physique moléculaire optique et hertzienne [CPMOH]
dc.contributor.authorCOGNET, Laurent
hal.structure.identifierDepartment of Experimental Therapeutics
dc.contributor.authorLEMOS, Robert Jr.
hal.structure.identifierDepartment of Chemistry
dc.contributor.authorLEEUW, Tonya
hal.structure.identifierDepartment of Experimental Therapeutics
dc.contributor.authorGUMBINER-RUSSO, Laura
hal.structure.identifierDepartment of Chemistry
dc.contributor.authorWEISMAN, R. Bruce
hal.structure.identifierDepartment of Experimental Therapeutics
dc.contributor.authorPOWIS, Garth
dc.date.created2008-12-11
dc.date.issued2009-04-17
dc.identifier.issn1998-0124
dc.description.abstractEnA new approach is described for delivering small interfering RNA (siRNA) into cancer cells by noncovalently complexing unmodifi ed siRNA with pristine single-walled carbon nanotubes (SWCNTs). The complexes were prepared by simple sonication of pristine SWCNTs in a solution of siRNA, which then served both as the cargo and as the suspending agent for the SWCNTs. When complexes containing siRNA targeted to hypoxiainducible factor 1 alpha (HIF-1\alpha) were added to cells growing in serum containing culture media, there was strong specific inhibition of cellular HIF-1\alpha activity. The ability to obtain a biological response to SWCNT/ siRNA complexes was seen in a wide variety of cancer cell types. Moreover, intratumoral administration of SWCNT- HIF-1\alpha siRNA complexes in mice bearing MiaPaCa-2 /HRE tumors signifi cantly inhibited the activity of tumor HIF-1 . As elevated levels of HIF-1\alpha are found in many human cancers and are associated with resistance to therapy and decreased patient survival, these results imply that SWCNT/siRNA complexes may have value as therapeutic agents.
dc.language.isoen
dc.publisherSpringer
dc.subject.ensiRNA
dc.subject.ensingle-walled carbon nanotubes
dc.subject.enanti-cancer therapy
dc.subject.enin vivo delivery agent
dc.title.enIn Vivo Therapeutic Silencing of Hypoxia-Inducible Factor 1 Alpha (HIF-1\alpha) Using Single-Walled Carbon Nanotubes Noncovalently Coated with siRNA
dc.typeArticle de revue
dc.identifier.doi10.1007/s12274-009-9026-7
bordeaux.journalNano Research
bordeaux.page279-291
bordeaux.volume2
bordeaux.issue4
bordeaux.peerReviewedoui
hal.identifierhal-00505889
hal.version1
hal.popularnon
hal.audienceInternationale
hal.origin.linkhttps://hal.archives-ouvertes.fr//hal-00505889v1
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Nano%20Research&rft.date=2009-04-17&rft.volume=2&rft.issue=4&rft.spage=279-291&rft.epage=279-291&rft.eissn=1998-0124&rft.issn=1998-0124&rft.au=BARTHOLOMEUSZ,%20Geoffrey&CHERUKURI,%20Paul&KINGSTON,%20John&COGNET,%20Laurent&LEMOS,%20Robert%20Jr.&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée